0.00Open8.58Pre Close0 Volume0 Open Interest42.00Strike Price0.00Turnover9356.27%IV2.78%PremiumDec 6, 2024Expiry Date7.21Intrinsic Value100Multiplier-5DDays to Expiry1.37Extrinsic Value100Contract SizeAmericanOptions Type0.9730Delta0.0121Gamma5.74Leverage Ratio-350.2428Theta0.0000Rho5.58Eff Leverage0.0000Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet